Thermo Fisher posted Q2 2026 revenue up 10% to USD 11.99 billion, including 5% organic growth.
GAAP diluted EPS rose 9% to USD 4.68; adjusted EPS climbed 13% to USD 6.03.
GAAP operating income increased 14% to USD 2.09 billion; operating margin widened 0.5 percentage points to 17.4%.
Adjusted operating income grew 15% to USD 2.73 billion; adjusted operating margin widened 0.9 percentage points to 22.8%.
The company repurchased USD 1 billion of stock and announced the divestiture of its microbiology business as customer activity continued to strengthen.
TMO•
